T 1319/04 (Dosage regimen/KOS LIFE SCIENCES, INC.) du 22.04.2008
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2008:T131904.20080422
- Date de la décision
- 22 avril 2008
- Numéro de l'affaire
- T 1319/04
- Requête en révision de
- -
- Numéro de la demande
- 94306847.8
- Classe de la CIB
- A61K 31/445
- Langue de la procédure
- Anglais
- Distribution
- Publiées au Journal officiel de l'OEB (A)
- Téléchargement
- Décision en anglais
- Autres décisions pour cet affaire
- T 1319/04 Hyperlipidemia/KOS LIFE SCIENCES, INC. 2010-12-30
- Résumés pour cette décision
- -
- Titre de la demande
- Nicotinic acid compositions for treating hyperlipidemia
- Nom du demandeur
- Kos Life Sciences, Inc.
- Nom de l'opposant
- -
- Chambre
- 3.3.02
- Sommaire
The following questions are referred to the Enlarged Board of Appeal for decision:
1. Where it is already known to use a particular medicament to treat a particular illness, can this known medicament be patented under the provisions of Articles 53(c) and 54(5) EPC 2000 for use in a different, new and inventive treatment by therapy of the same illness?
2. If the answer to question 1 is yes, is such patenting also possible where the only novel feature of the treatment is a new and inventive dosage regime?
3. Are any special considerations applicable when interpreting and applying Articles 53(c) and 54(5) EPC 2000?
- Dispositions juridiques pertinentes
- European Patent Convention Art 52(4) 1973European Patent Convention Art 53(c)European Patent Convention Art 54(5)European Patent Convention Art 54(5) 1973
- Mots-clés
- Allowability of dosage regimen - under Articles 52(4) and 54(5) EPC 1973 and under Articles 53(c) and 54(5) EPC 2000 - referral to Enlarged Board
- Exergue
- -
ORDER
For these reasons it is decided that:
The following questions are referred to the Enlarged Board of Appeal for decision:
1. Where it is already known to use a particular medicament to treat a particular illness, can this known medicament be patented under the provisions of Articles 53(c) and 54(5) EPC 2000 for use in a different, new and inventive treatment by therapy of the same illness?
2. If the answer to question 1 is yes, is such patenting also possible where the only novel feature of the treatment is a new and inventive dosage regime?
3. Are any special considerations applicable when interpreting and applying Articles 53(c) and 54(5) EPC 2000?